Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SJALL23T: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

NCT06390319 is registered in ClinicalTrials.gov with St. Jude Children's Research Hospital as lead sponsor.

NCT NCT06390319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06390319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SJALL23T: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Lead sponsor
St. Jude Children's Research Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 27, 2024
Completion date
December 31, 2033
Enrollment
100 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

mixed phenotype acute leukemia, t-cell acute lymphoblastic leukemia, t-cell lymphoma